Plus Therapeutics Completes Enrollment of Cohort 1 ReSPECT-LM Phase 1/2a Trial (GlobeNewswire) - Jun 16, 2022 - "Plus Therapeutics, Inc...announced the completion of enrollment in the first cohort of the ReSPECT-LM Phase 1/2a dose escalation clinical trial of Rhenium-186 NanoLiposome (186RNL) for the treatment of leptomeningeal metastases (LM)...'We intend to provide enrollment and complete clinical updates in the third quarter of 2022'."
Clinical • Enrollment closed • Oncology
|